Our helpline: 01924 200799 Mon-Fri, 9am-4pm

Alife2

The Alife2 study is investigating whether anti-coagulant (blood–thinning) treatment reduces the risk of miscarriage in women with two or more (unexplained) miscarriages and inherited thrombophilia – a blood-clotting problem.

If you might be interested in taking part in the Alife2 trial, here’s what you need to know:

Who can take part?

You may be able to take part in the trial if a blood test shows that you have inherited thrombophilia AND

What would I need to do?

Participants randomised to trial treatment will be instructed in how to inject themselves once daily with a dose of anti-coagulant in either upper leg or abdomen. Treatment would start at or within 7 weeks of a confirmed pregnancy (based on first day of the last period) and continue until the start of labour or the end of the pregnancy.

Participants who are randomised to standard care won’t need to inject themselves at all, but will be given normal pregnancy care, although they will be followed up by the research team.

Where is it taking place?

 The following hospitals are currently recruiting patients

New centres are opening regularly.

Please ring 02476 964 983 to speak to the Clinic Secretary about your interest in this research. Your eligibility for the study will be assessed and if you are eligible you will be given further information about how to take part.